Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions

J Am Coll Cardiol. 2003 May 21;41(10):1725-31. doi: 10.1016/s0735-1097(03)00298-5.

Abstract

Objectives: We analyzed the effects of vascular brachytherapy (VBT) on ostial in-stent restenosis (ISR).

Background: In-stent restenosis has a high recurrence rate after percutaneous reintervention. The recurrence rate of ostial ISR lesions and the impact of VBT remain unknown.

Methods: We evaluated 133 patients with native coronary ostial ISR from a pooled database of 990 patients enrolled in randomized VBT trials. Independent quantitative angiography was performed at baseline and follow-up in 45 gamma, 27 beta, and 61 placebo patients.

Results: Binary restenosis was significantly higher in placebo than radiated patients (75.4% vs. 17.8% in gamma vs. 22.2% in beta, p < 0.0001). The treatment effect of both gamma (odds ratio [OR] 0.06; 95% confidence interval [CI] 0.02 to 0.17) and beta VBT (OR 0.10; 95% CI 0.03 to 0.31) was maintained after controlling for differences in baseline lesion length. Proximal and distal radiation edge restenosis rates were similar among the groups. Vascular brachytherapy of true aorto-ostial lesions (n = 34) was similarly beneficial: restenosis rates of placebo versus gamma or beta patients of 83.3% versus 6.7% versus 28.6%, p = 0.0002.

Conclusions: Conventional treatment of ostial ISR is associated with a recurrence rate of over 75%. Vascular brachytherapy with either gamma or beta sources results in significant and similar reductions in restenosis compared with placebo. Similar benefits after VBT prevail in true aorto-ostial lesions.

Publication types

  • Clinical Trial
  • Meta-Analysis
  • Randomized Controlled Trial

MeSH terms

  • Aorta / pathology
  • Beta Particles / therapeutic use
  • Brachytherapy*
  • Cineangiography
  • Coronary Angiography
  • Coronary Restenosis / diagnostic imaging
  • Coronary Restenosis / pathology
  • Coronary Restenosis / radiotherapy*
  • Coronary Vessels / pathology
  • Gamma Rays / therapeutic use
  • Humans
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Stents*